01 — What is it?
Selank is a heptapeptide studied primarily in Russian clinical literature for anxiety and related symptoms. Proposed biology includes modulation of enkephalin metabolism and immune signaling.
Database / Research Profiles / Selank
RESEARCH PROFILE
SELANK
Thr-Lys-Pro-Arg-Pro-Gly-Pro • anxiolytic peptide
Neuro / anxietyLimited human clinical evidence
EVIDENCE SNAPSHOTLIMITED HUMAN CLINICAL EVIDENCE
Human studies exist, but evidence is limited and not comparable to large regulatory drug-development programs in North America.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Neuro / anxiety. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: YESPersonal dosing protocol: NOT PROVIDED
Human studies exist, but evidence is limited and not comparable to large regulatory drug-development programs in North America.
04 — Mechanism / biology
Selank is a heptapeptide studied primarily in Russian clinical literature for anxiety and related symptoms. Proposed biology includes modulation of enkephalin metabolism and immune signaling.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.